Clearside Biomedical to Present at the JMP Securities Life Sciences Conference
11 Junio 2019 - 6:05AM
Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical
company dedicated to developing treatments that restore and
preserve vision for people with serious eye diseases, announced
today that Thomas A. Ciulla, M.D., MBA, Chief Medical Officer will
present a company overview at the JMP Securities Life Sciences
Conference in New York, NY on Wednesday, June 19, 2019 at 10:30
a.m. ET.
A link to the live and archived webcast may be
accessed on the Clearside website under the Investors section:
Events and Presentations. An archive of the webcast will be
available for three months.
About Clearside Biomedical
Clearside Biomedical, Inc. is a
biopharmaceutical company dedicated to developing treatments that
restore and preserve vision for people with serious eye diseases.
Clearside’s proprietary suprachoroidal treatment approach offers
unprecedented access to the back of the eye where sight-threatening
disease often occurs. The Company’s unique Suprachoroidal Space
(SCS) Injection Platform for eye disease treatments is an
inherently flexible and non-surgical procedure, intended to work
with established medications, new formulations of medicines, as
well as future therapeutic innovations such as gene therapy.
Clearside is headquartered in Alpharetta, GA. For more information,
please visit http://www.clearsidebio.com.
Investor and Media Contacts: Jenny Kobin Remy
Bernarda ir@clearsidebio.com(678) 430-8206
Source: Clearside Biomedical, Inc.
Clearside Biomedical (NASDAQ:CLSD)
Gráfica de Acción Histórica
De Jun 2024 a Jul 2024
Clearside Biomedical (NASDAQ:CLSD)
Gráfica de Acción Histórica
De Jul 2023 a Jul 2024